Do you offer compounded semaglutide or tirzepatide?

Not as a general offering. The FDA declared the semaglutide and tirzepatide shortages resolved, which ended the basis on which pharmacies could compound copies of them, and enforcement discretion for outsourcing facilities ended in March 2025. What remains available is the FDA-approved branded product, and genuine patient-specific compounding only where a prescriber documents a clinical need the approved product cannot meet. Any provider offering compounded copies as a routine low-cost alternative is operating outside that framework.